Prostate, Bladder Cancer Care Delays Common During Pandemic
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
Strategies such as booster doses appear warranted in this population.
Patients with poor performance status have been excluded from pivotal trials on metastatic renal cell carcinoma.
Both genetic and lifestyle factors interact to increase the risks for renal cell carcinoma, investigators reported.
The proportion of patients with chronic kidney disease who die from cancer may be underappreciated.
Study confirms the care gap in bone health management and fracture prevention among older men with prostate cancer receiving androgen deprivation therapy.
The risk for kidney failure requiring renal replacement therapy varies by cancer type, with multiple myeloma associated with the highest risk.
In patients with high-risk prostate cancer, negative PSMA PET/CT does not permit PLND avoidance, investigators cautioned.